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Abstract. Invasion of human erythrocytes by Plasmodium vivax requires interaction between Duffy binding protein
(PvDBP) and the Duffy blood group antigen. The receptor-binding domain of PvDBP lies in a conserved N-terminal,
cysteine-rich region, region II (PvRII). PvRII is a valuable malaria subunit vaccine candidate for asexual blood stages.
We have evaluated in Aotus monkeys the immunogenicity and protective efficacy of recombinant PvRII formulated in
Freund’s and Montanide ISA720 adjuvants. Specific antibody titers were determined by an enzyme-linked immunosor-
bent assay after each of three doses of 50 g of protein administered by the subcutaneous route. Immunization with
PvRII formulated in Freund’s adjuvant yielded higher antibody titers than immunization with the Montanide ISA720
formulation and offered partial protection. Although the Montanide ISA720 formulation was immunogenic, it did not
provide any protection. Given the immunogenicity and partial protection observed, further studies are needed to
optimize the PvRII vaccine formulation with adjuvants suitable for human use.
INTRODUCTION
Over the last two decades, important efforts have been
made to identify and test malaria vaccine candidates that
could be used to diminish the enormous socioeconomic and
health burden that malaria represents for disease-endemic
communities in tropical countries.1 Plasmodium vivax is the
second most prevalent human malaria parasite worldwide,
accounting for approximately 20% of malaria cases globally
and 80–90% of cases in Asia, Oceania, and the Americas.2
Because of its lower prevalence, lower rates of mortality, and
the lack of methods for continuous in vitro culture, limited
resources have been made available for P. vivax malaria vac-
cine research.
The P. vivax Duffy binding protein (DBP) represents a
valuable malaria subunit vaccine candidate for asexual blood
stages. The protein is a conserved antigen expressed on the
merozoite surface and it has been demonstrated to be a ligand
for parasite invasion of the erythrocyte through a specific
interaction with the Duffy blood group antigen (Fy), recently
renamed the Duffy antigen receptor for chemokines (DARC)
because of its role in chemokine binding.3 DARC is an indis-
pensable receptor for P. vivax invasion of human erythrocyte,
and individuals lacking DARC (i.e., Fy-negative individuals)
are naturally protected from P. vivax–induced clinical ma-
laria.4 The immune blockage of this receptor-ligand interac-
tion through the induction of antibodies to PvDBP is there-
fore likely to protect humans against P. vivax blood infection.
PvDBP belongs to a family of erythrocyte binding proteins
that includes the P. falciparum sialic acid binding protein, also
known as 175 kD erythrocyte binding antigen, P. knowlesi
DBP (PkDBP), and P. knowlesi  and  proteins. The recep-
tor-binding domains of these proteins lie in conserved, N ter-
minal, cysteine-rich regions (region II) that are found in all of
these proteins. Region II of PvDBP (PvRII) contains ap-
proximately 350 amino acids with 12 conserved cysteine resi-
dues.3,5
Because of its potential use as a subunit malaria vaccine,
methods to produce recombinant PvRII in its functional con-
formation by expression in Escherichia coli followed by in
vitro refolding and purification have been recently estab-
lished.6 Recombinant PvRII is recognized by antibodies of
malaria-exposed individuals,7,8 and immunization studies
have indicated that the protein is highly immunogenic in rab-
bits, and mice, and elicits high-titer binding inhibitory anti-
bodies.6,9
Following natural exposure to P. vivax infection, individu-
als residing in malaria-endemic areas develop antibodies that
block binding of PvDBP to DARC-positive erythrocytes.8
Studies in Papua New Guinea also show that cellular and
humoral immune responses to PvRII develop progressively
with age in residents from P. vivax–endemic areas, suggesting
they are implicated in acquired immunity to P. vivax.8,10,11
Importantly, antibodies raised against the homologous bind-
ing domain of PkDBP (PkDBP-RII) block the invasion of
human Duffy-positive erythrocytes by P. knowlesi in vitro,
providing further support for developing a recombinant vac-
cine based on PvRII.12
Rabbits immunized with PvRII formulated in Freund’s ad-
juvant, as well as mice immunized with PvRII formulated with
the human compatible adjuvants Montanide ISA720 and
ASO2A, develop high-titer binding inhibitory antibodies that
block the binding of Duffy positive erythrocytes to COS-7
cells expressing PvRII on their surface.6,9 However, the pro-
tective efficacy of immunization with PvRII against parasite
challenge has not yet been demonstrated. In the present
study, we assess the immunogenicity and protective efficacy
of PvRII formulated in Freund’s adjuvant and the human
adjuvant Montanide ISA 720 against blood-stage challenge
with P. vivax.
MATERIALS AND METHODS
Recombinant protein. The recombinant protein was ex-
pressed in E. coli, refolded, and purified in its functional con-
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formation as described previously.6 Briefly, a plasmid con-
taining the gene encoding the P. vivax DBP was used as a
template to amplify the gene fragment encoding the PvRII
region (amino acids 194–521) fused to hexa-histidine (6-His)
at the C-terminal end. The polymerase chain reaction product
was digested and cloned as a Nco I-Sal I fragment, then ex-
pressed in the vector pET28a+ (Novagen, Madison, WI). The
resultant plasmid was used to transform E. coli and expres-
sion of recombinant PvRII was induced with 1 mM isopropyl-
-D-thiogalactopyranoside. Recombinant PvRII was purified
from inclusion bodies under denaturing conditions by metal
affinity chromatography, refolded by the method of rapid di-
lution, and purified to homogeneity by ion exchange chroma-
tography as previously described.9
Aotus monkeys and immunization. Aotus lemurinus grise-
imembra monkeys from the Primate Center in Cali, Colombia
were used for this study. Adult, naive male and female ani-
mals were selected for weight (> 800 grams), age (> 2 years
old), and presence of normal liver and kidney functions be-
fore immunization. The animal experimental protocol was re-
viewed and approved by the Animal Ethical Committe of the
Universidad del Valle. The study was conducted in compliance
with National Institutes of Health guidelines for animal use.
A total of 24 monkeys (6 per group) were arbitrarily as-
signed to two experimental groups (A and C) and two con-
trols groups (B and D). Group A was immunized with 50 g
of recombinant PvRII (rPvRII) formulated in completed
Freund’s adjuvant and incomplete Freund’s adjuvant in a 50:
50 ratio. Group C was immunized with rPvRII formulated in
Montanide ISA 720 in a 7:3 antigen:adjuvant ratio, as recom-
mended by the adjuvant manufacturer (Seppic, Inc., Paris,
France). Groups B and D were injected with distilled water
containing no protein and emulsified with Freund’s adjuvant
and Montanide ISA-720, respectively. Each animal was im-
munized by subcutaneous injection at five different sites on
the back on days 0, 30, and 60.
Hematologic parameters (hemoglobin level, hematocrit,
liver and kidney functions, blood urea nitrogen, aspartate
aminotransferase, and alanine aminotransferase) were evalu-
ated before and during the immunization process to check the
safety of the vaccine candidate. After challenge, if animals
developed a hematocrit below 25%, they were treated with a
combination of sulfadoxine-pyrimethamine.13
Antibody responses. Plasma fractions were separated by
centrifugation from whole blood collected from immunized
and control monkeys before each vaccination and before
challenge. Plasma fractions were kept at −70°C until used for
detection of specific antibodies to PvRII using an enzyme-
linked immunosorbent assay (ELISA) antibodies to parasites
using an immunofluorescence assay (IFA).
Enzyme-linked immunosorbent assay. Plates (Maxisorp;
Nunc, Roskilde, Denmark) were coated for two hours at 37°C
with 100 L/well of rPvRII at a concentration of 2 g/mL in
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6).
The plates were then blocked with 2.5% bovine serum albu-
min (BSA) in phosphate-buffered saline (PBS), pH 7.4, over-
night at 4°C, washed with PBS 1× pH 7.2 tween 20 at 0.05%
and incubated for one hour at 37°C in duplicate with 10-fold
or two-fold serial dilutions of plasma from immunized Aotus
monkeys containing 1% BSA. The plates were washed with
PBS 1× pH 7.2 tween 20 at 0.05% incubated for one hour
with peroxidase-conjugated rabbit anti-Aotus IgG (pro-
duced at the Malaria Vaccine and Drug Development Center,
Cali, Colombia and conjugated at Absea Biotechnology Ltd.,
Beijing, People’s Republic of China) diluted 1:1,000, and in-
cubated with 100 L of the substrate peroxidase solution.
Absorbance was read at 630 nm (OD630) in a multi-channel
spectrophotometer (MRX; Dynex Technologies, Inc., Chan-
tilly, VA). To define the cut-off value, we tested the antigen
using sera from 10 Aotus monkeys with no history of malarial
infection or vaccination. The ELISA results were considered
positive when absorbance of the test sera was greater than or
equal to the mean value of Aotus control plasma OD630 plus
3 standard deviations.
Enzyme-linked immunosorbent assay–based binding as-
say. To study the ability of Aotus antibodies to block binding
of PvRII an ELISA-based binding assay was carried out as
described elsewhere.14 Briefly, rPvRII at a concentration of
0.1 g/mL was pre-incubated for one hour at room tempera-
ture with five-fold serial dilutions of individual Aotus serum
samples from days 60 and 90 after immunization in duplicate
and allowed to bind to ELISA microplates coated with re-
combinant Duffy antigen at a concentration of 1 g/mL. Fifty
percent inhibition titers were determined from curves ob-
tained by plotting percentage binding at different dilutions of
sera compared with binding with no sera.
Immunofluorescence assay. The IFA was performed using
air-dried smears of asexual blood stages of the P. vivax Sal-
vador I strain derived from an infected Aotus monkey. Para-
sites were purified using a modification of a method described
elsewhere.15 Briefly, whole infected blood was collected and
leukocytes were removed by passage through a loosely
packed CF 11 cellulose powder column previously washed
with RPMI 1640 medium. The effluent was centrifuged at 500
× g for 10 minutes at room temperature and resuspended at a
50% hematocrit. We examined thick and thin Giemsa-stained
blood films to reconfirm parasite stage. The parasite fraction
was enriched using a 47% Percoll gradient and the top cell
layer was removed, washed three times with RPMI medium
without serum and cultured for 40 hours using the candle jar
culture. The IFA slides were prepared with mature schizonts
and were stored at −70°C until use. After de-hemoglobini-
zation and fixation in acetone for five minutes, slides were
incubated with test plasma diluted 1:50 in PBS for one hour
and washed with PBS. Fluorescein-conjugated affinity-
purified rabbit anti-Aotus IgG (produced at Malaria Vaccine
and Drug Development Center and conjugated at Absea Bio-
technology, Ltd.) was added, and incubated for one hour at
room temperature. After additional washings with PBS 1× pH
7.2, the slides were overlaid with 30% glycerol and examined
with an ultraviolet epifluorescence microscope.
Parasite challenge and parasitemia follow-up. One month
after last immunization (on day 90), all monkeys were intra-
venously challenged with 105 P. vivax Salvador I blood-stage
parasites. Plasmodium vivax Salvador I was kindly provided
by Dr. William Collins (Centers for Disease Control and Pre-
vention, Atlanta, GA) and maintained as a frozen stabilate in
liquid nitrogen until use. An Aotus monkey was infected with
the thawed parasites and used as a parasite donor for the
challenge studies. We initially assessed parasitemia by thick
blood smear until it was detectable. The parasitemia was then
quantified by scoring the frequency of infected erythrocytes
in thin blood smears stained with Giemsa. Parasitemia was
checked three times a week for 39 days (i.e., up to day 129)
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when all animals were treated with 25 mg of sulfadoxine-
pyrimethamine.
Statistical analysis. We evaluated three efficacy outcomes:
prepatent period, maximum parasitemia, and total parasit-
emia estimated as area under the curve (AUC). The AUC
was calculated using the trapezoid rule. Samples that tested
positive for parasitemia by thick smear that were not quanti-
fiable by thin smear were treated as 0% in the AUC calcu-
lation. Differences between experimental and control groups
(A versus B, C versus D) were tested using a two-sided Wil-
coxon rank sum test (Stata version 8.0; Stata Corporation,
College Station, TX).
RESULTS
Antibody responses to rPvRII. We demonstrated that im-
munization of A. l. griseimembra monkeys with rPvRII in-
duced high-titer specific antibodies (Table 1). Substantial in-
creases in the specific anti-rPvRII end point ELISA titers
(2–5.6 × 106) were observed in all animals immunized (day 90)
with rPvRII formulated in Freund’s adjuvant (group A). Ani-
mals immunized with PvRII formulated in Freund’s adjuvant
developed approximately four-fold higher endpoint titers
than animals immunized with PvRII formulated in Montanide
ISA 720 (0.6–20 × 104, group C). No reactivity against PvRII
was found in the corresponding control groups (B and D).
Sera from three monkeys from group A (079*032, 301*630,
and 276*614) showed reactivity to the parasite, as shown by
the IFA at a serum dilution of 1:50.
Inhibition of binding of PvRII to DARC by Aotus
sera. Sera obtained on day 60 from monkeys immunized with
rPvRII formulated in Freund’s adjuvant showed the highest
binding inhibition titers with 50% inhibition titers ranging
from 1:1,650 to 1:46,200 (Table 2). High-binding inhibition
titers in the Freund’s group (group A) are associated with a
longer pre-patent period (Table 3). The 50% binding inhibi-
tion titers for the Montanide ISA 720 group (group C) ranged
from < 1:10 to 1:99 on day 60 with moderate increases on day
90. However, these values were much lower than those ob-
served for the Freund’s adjuvant group (group A) on day 60
and were insufficient to provide any protection. Due to small
amounts of sera available, day 90 sera from group A could not
be tested in binding inhibition assays.
Parasite challenge and parasitemia follow-up. As shown in
Table 3 and Figure 1, all animals from both the experimental
and control groups became infected after parasite challenge.
Overall pre-patency was longer and parasitemia levels were
lower for vaccinated monkeys in group A compared with con-
trol group B. Five of the six animals in group B had a pre-
patent period of seven days by thick blood smear, whereas in
experimental group A, all animals were negative (Table 2).
The median number of days to patency was 7 days for group
B and 16 days for group A (Table 4). The median peak par-
asitemia was 0.25% for group B and 0.1% for group A. The
median AUC for group B was nearly four times greater than
the median AUC for group A (Table 4). However, only the
differences in pre-patency distributions between groups A
and B reached statistical significance (P < 0.05).
In group C, all animals developed detectable parasitemia
by thick blood smear by day 7 or day 9 (Table 3). All animals
from the corresponding control group (group D) had detect-
able parasitemias on day 7. The median number of days to
patency was eight days for group C and seven days for group
D (Table 3). The median peak parasitemia was 0.1% for
group C and 0.2% for group D. The median AUC for group
D was nearly twice as high as the median AUC for group C
(Table 4). In contrast to groups A and B, which were immu-
nized with Freund’s adjuvant, the differences between experi-
mental and control groups C and D immunized with Mon-
tanide ISA 720 was not as large. No statistically significant
differences were observed between groups C and D.
Other clinical outcomes. Animals immunized with Freund’s
adjuvant developed granulomas, but the severity of the toxic
reactions was smaller than that observed in studies using
other malaria proteins, as well as in a pilot study using the
same protein.
A slight decrease in the levels of hemoglobin was observed
in three (monkey 355*782, 9.7 g/dL; 301*630, 11.1 g/dL; and
079*032, 12.4 g/dL) of the six animals immunized with the
rPvRII formulated in Freund’s adjuvant at day 90 in compari-
son with only one monkey that showed a similar decrease in
the control group (077*552, 9 0.6 g/dL). However, these
changes remained in the normal range (13.1–23.4 g/dL) and
were not clinically significant. In contrast, animals immunized
with the rPvRII formulated in Montanide ISA-720 had nor-
mal hemoglobin levels during the immunization period. We
observed normal leukocyte values in the groups immunized
with Montanide, but the number of leukocytes increased in
some of the animals immunized with Freund’s adjuvant.
All animals in this trial were subjected to liver and kidney
function tests to determine the safety of the vaccine, particu-
larly when formulated in Montanide ISA-720. No clinically
significant differences in hematologic, liver, or kidney param-
eters were observed during the immunization period in either
experimental or control group.
DISCUSSION
Duffy binding protein is a parasite ligand used by P. vivax
for invasion of human erythrocytes through a specific inter-
action with DARC on the red blood cell surface. Because of
the potential of the receptor-binding domain, PvRII of DBP
TABLE 1
Kinetics of rPvRII-DBP-specific antibodies in Aotus monkeys*
Group Monkey code
Day of bleedings
ELISA† IFA
0 30 60 90 90
A 301*630 0 1,000 1,800 5,200 Neg
rPvRII-DBP 079*032 0 1,000 1,400 5,000 Neg
Freund 355*782 0 1,000 1,600 4,000 Neg
383*845 0 500 1,200 2,000 50
276*614 0 500 1,400 5,600 50
378*513 0 500 4,800 2,000 50
C 119*853 0 5 8 6 Neg
rPvRII-DBP 565*377 0 10 50 100 Neg
Montanide 531*108 0 8 16 20 Neg
358*363 0 5 50 50 Neg
120*339 0 10 80 200 Neg
353*126 0 50 80 100 Neg
* rPvRII-DBP  recombinant Plasmodium vivax Duffy binding protein; ELISA 
enzyme-linked immunosorbent assay; IFA  immunofluorescence assay.
† Values are reciprocal dilution titers × 103.
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as a vaccine candidate for human use, we assessed the immu-
nogenicity and protective efficacy of rPvRII formulated in
both Freund’s adjuvant and Montanide ISA 720. Freund’s
adjuvant commonly yields high-titer antibodies in animal
studies and was thus used as a positive control. Montanide
ISA720 has been successfully used in multiple malaria clinical
trials in humans with very limited or no adverse events.16
We found that the Freund’s formulation of the protein was
more immunogenic than the formulation with Montanide
ISA-720. More importantly, vaccination with rPvRII formu-
lated in Freund’s adjuvant partially protects Aotus monkeys
from experimental parasite challenge. All parameters exam-
ined were strongly suggestive of efficacy. However, except for
the longer pre-patency period in the rPvRII-Freund’s group,
the differences between vaccinated and control groups were
not statistically significant due to the small sample sizes.
Immunization of Aotus with rPvRII formulated in Freund’s
adjuvant not only substantially delayed the appearance of
patent parasitemia at a statistically significant level (P 
0.004), but also decreased the magnitude of parasitemia in
most animals. These results are consistent with those of an
earlier pilot study in which we observed complete protection
in three of five Aotus monkeys immunized with 100 g of
rPvRII formulated in Freund’s adjuvant. In both experiments,
immunization with this diluted formulation of Freund’s adju-
vant induced granuloma, a toxic effect that will not be accept-
able in humans. Here, we have observed cutaneous lesions
such as inflammation at the sites of inoculation, and granu-
loma formation without further complications. Bacteriologic
examination failed to demonstrate the presence of acid-fast
microorganisms and other opportunistic microorganisms.
With the aim of assessing the protective efficacy of a vac-
cine formulation composed of rPvRII and an adjuvant suit-
able for human use, we selected Montanide ISA720. In pre-
TABLE 2
Fifty percent inhibition titers of sera from individual Aotus monkeys
immunized with rPvRII-DBP*
Group Monkey code
Day of bleedings†
60 90
A 301*630 42,600 ND
rPvRII-DBP 079*032 2,049 ND
Freund 355*782 17,172 ND
383*845 1,840 ND
276*614 1,650 ND
378*513 1,808 ND
C 119*853 < 10 16
rPvRII-DBP 565*377 35 214
Montanide 531*108 51 253
358*363 50 89
120*339 99 155
353*126 63 366
* rPvRII-DBP  recombinant Plasmodium vivax Duffy binding protein; ND  not de-
termined.
† Values are reciprocal dilution titers.
FIGURE 1. Course of Plasmodium vivax infection in Aotus monkeys immunized with recombinant P. vivax Duffy binding protein.
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vious studies, this adjuvant has been used with rPvRII to
immunize mice9 and with other proteins to immunize mon-
keys.17 Similar to the results found in the mice study,9 we
report that Aotus sera raised against rPvRII are able to block
the binding of rPvRII to recombinant DARC in vitro. In the
group immunized with the Montanide ISA720 formulation,
the binding inhibition titers were related to the end point
titers, with both titers increasing from day 60 to day 90. In the
group immunized with the PvRII-Freund’s formulation, Mon-
key 301*630 showed the highest 50% binding inhibition titer
(1:42,600), which was associated with a delay in patency (day
21). However, the antibody titers achieved could not block
the development of parasitemia in monkeys directly chal-
lenged by inoculation with live P. vivax parasites.
High antibody titers are necessary for effective blocking of
parasite invasion and growth in vivo. Monkey 378*513, which
developed the earliest patency in the Freund’s group (group
A), had a low binding inhibition titer on day 60. Only half of
the sera from group A (Freund’s group) could recognize na-
tive PvDBP in the parasite by IFA, whereas none of the sera
from group C (Montanide group) could recognize native
PvDBP. Inability to detect PvDBP in merozoites may be due
to technical difficulties in the IFAs given the small amounts of
PvDBP present. Since immunoglobulin subtyping reagents
are not available for Aotus monkeys, it was not possible to
study any possible correlation of immunoglobulin subtypes
with protection.
This study suggests that to achieve protection, antibodies to
TABLE 4
Characteristics of distributions of percentage parasitemia outcomes measured by group*
Adjuvant Immunogen Parasitemia Median Minimum Maximum P vs control
Freund Group A rPvRII-DBP Prepatency 16 9 21 0.004
Peak 0.1 0.1 0.3 0.149
AUC 0.56 0.27 2.6 0.200
Group B PBS Prepatency 7 7 9
Peak 0.25 0.1 0.5
AUC 2.08 0.2 8.45
Montanide Group C rPvRII-DBP Prepatency 8 7 9 0.056
Peak 0.1 0.05 0.4 0.173
AUC 0.75 0.25 2.23 0.229
Group D PBS Prepatency 7 7 7
Peak 0.2 0.1 0.4
AUC 1.31 0.7 2.73
* rPvRII-DBP  recombinant Plasmodium vivax Duffy binding protein; AUC  area under percent parasitemia curve; PBS  phosphate-buffered saline.
TABLE 3
Parasitemia follow-up in Aotus monkeys*
Group
Monkey
code
Day
0 7 9 11 14 16 18 21 23 25 28 30 32 35 37 39 Peak† AUC
A 301*630 − − − − − − − + + 0.1 0.1 0.1 0.1 0 0 0 0.1 0.95
rPvRII-DBP 079*032 − − − − − − − + + 0.1 0 0.01 0 0 0 0 0.1 0.27
Freund 355*782 − − − − − + + 0.05 0.1 0.05 0 0 0 0 0 0 0.1 0.45
383*845 − − − − − + + 0.1 0.05 0.1 0 Dead 0.1 0.6
276*614 − − − + + + 0.1 0.05 0.01 0.05 0 0 0 0 0 0 0.1 0.52
378*513 − − + 0.05 0.25 0.3 0.3 0.2 0 0 0 0 0 0 0 0 0.3 2.6
B 077*552 − + + + + + + + + + + 0.1 0 0 0 0 0.1 0.2
PBS 516*021 − + + + + 0.1 0.1 0.05 0.1 0.05 0.1 0.1 0 0 0 0 0.1 1.35
Freund 337*291 − + + + 0.1 0.1 0.3 0.3 0.05 0.05 0 0 0 0 0 0 0.3 2.18
529*121 − − + 0.1 0.1 0.3 0.3 0.05 0.05 0.1 0 0 0 0 0 0 0.3 2.33
366*005 − + 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.05 0 0 0 0 0 0 0.2 1.98
578*069 − + 0.1 0.3 0.3 0.5 0.2 0.2 0.4 0.3 0.3 0.4 0.3 0.2 0.2 0.2 0.5 8.45
C 119*853 − − + + + + + + + 0.05 0.01 0.1 0.1 0 0.1 0.1 0.1 0.8
rPvRII-DBP 565*377 − − + + + + 0.05 0.05 0 0 0 0 0 0 0 0 0.05 0.25
Montanide 531*108 − − + + + 0.05 0.1 0.1 0 0 0 0 0 0 0 0 0.1 0.6
358*363 − + + 0.1 0 0.1 0.1 0 0 0 0 0 0 0 0 0 0.1 0.7
120*339 − + + 0.1 0.2 0.2 0.1 0.1 0 0 0 0 0 0 0 0 0.2 1.65
353*126 − + + 0.1 0.4 0.3 0.1 0.05 0 0 0 0 0 0 0 0 0.4 2.23
D 527*098 − + + + + + + 0.1 0.1 0.1 0 0 0 0 0 0 0.1 0.7
PBS 305*035 − + + + 0.05 0.1 0.1 0.2 0.05 0 0 0 0 0 0 0 0.2 1.18
Montanide 556*065 − + + 0.05 0.1 0.2 0.1 0 0 0 0 0 0 0 0 0 0.2 1.03
338*521 − + + 0.01 0.1 0.35 0.4 0.3 0 0 0 0 0 0 0 0 0.4 2.73
264*366 − + 0.05 0.05 0.1 0.3 0.1 0.05 0 0 0 0 0 0 0 0 0.3 1.45
362*617 − + 0.1 0.1 0.1 0.2 0.1 0.1 1.01 0.1 0 0 0 0 0 0 0.2 2.05
* Parasitemia by thick smear is reported as positive (+) or negative (−) whereas parasitemia by thin smear is reported as a percentage. AUC area under curve; rPvRII-DBP recombinant
Plasmodium vivax Region II—Duffy binding protein; PBS  phosphate-buffered saline. All other results for days 0–7 were negative.
† Maximum percentage.
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DBP, particularly the fraction able to cross-react with the
native protein, must be at sufficiently high levels to efficiently
block erythrocyte invasion by P. vivax merozoites. The partial
protection achieved in the Freund’s group suggests that a
potent adjuvant will be required for use in humans. PvDBP is
expressed in small quantities for a limited time starting late in
schizogeny and is localized intracellularly in micronemes.18 It
is likely to be on the apical surface only briefly once the
invasion process is initiated. Antibodies directed against
PvDBP would need to be in abundant amounts and have high
binding rates and high binding affinities to efficiently block
the binding of P. vivax merozoites to DARC.
In addition, although a monkey model is usually not used to
test safety of malaria vaccine candidates, in this study we
found that certain parameters such as hematologic, liver, and
kidney functions could be evaluated and thus provided useful
information on the effect of the protein during immunization.
In this regard, the use of Montanide ISA-720 eliminated con-
cerns related to the potential toxicity of vaccination with a
protein that binds the chemokine receptor DARC on eryth-
rocytes. Animals from group C immunized with rPvRII for-
mulated in Montanide ISA-720 and those from group that D
that only received the adjuvant did not show any detectable
toxic effect.
A recent clinical study using ASO-2A adjuvant (Glaxo-
SmithKline, Research Triangle Park, NC) and a recombinant
hybrid protein derived from the P. falciparum circumsporo-
zoite protein reported high levels of antibodies that protected
human volunteers from natural malaria infection.19 More-
over, other adjuvants such as Montanide ISA-51, which are
suitable for human use, can induce strong antibody responses
likely to efficiently block parasite reinvasion.20 We conclude
that the rPvRII vaccine candidate is immunogenic, and par-
tially protective in Aotus monkeys, and that it has promising
potential for further use in clinical trials. However, to achieve
higher levels of protective antibodies for this promising pro-
tein, new and more powerful adjuvants suitable for human
need to be identified.
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